Esophageal squamous cell carcinoma · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
DCF Variant #01 | — | R 3 508 | 21d | — | — | 2 | R 7 015 PFS proxy | 1 |
Cisplatin and Etoposide (EP) Variant #22 | — | R 1 819 | 21d | — | 16.0 mo | 6 | R 10 916 PFS proxy | 1 |
Cisplatin and Fluorouracil (CF) Variant #01 | — | R 1 783 | 28d | — | 26.1 mo | 3 | R 5 350 PFS proxy | 2 |
Cisplatin and Paclitaxel (TP) Variant #02 | — | R 1 315 | 21d | — | 27.5 mo | 7 | R 9 204 PFS proxy | 3 |
No neoadjuvant therapy Partial | — | — | — | — | 18.0 mo | — | — | 2 |
5 of 5 regimens shown